![Giovanni Ferrara](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Giovanni Ferrara
Directeur Général chez
Courage Therapeutics, Inc.
Profil
Giovanni A. Ferrara is currently Chief Executive Officer at Courage Therapeutics, Inc. since 2025, President, Chief Executive Officer & Director at Medeor Therapeutics, Inc. since 2023, and Partner at Novartis Venture Fund.
Former roles include Chief Executive Officer at Targanta Therapeutics, Inc. in 2000; President & Chief Executive Officer at Medeor Therapeutics, Inc.; President, Chief Executive Officer & Director at NeuroVia, Inc.; Director at Agilix Corp., Nucleonics, Inc., Thesan Pharmaceuticals, Inc., Spectral Genomics, Inc., and Akebia Therapeutics, Inc.; Managing Director at Burrill LLC from 2001 to 2009; Chief Business Consultant at Sorbent Therapeutics, Inc. in 2011; Financial Analyst at Letko Brosseau Investment Management, Inc. in 1997; Manager at GeneChem Management, Inc. from 1997 to 2001; and Venture Partner at Novartis Venture Funds (USA) from 2011 to 2018.
Education includes graduate and MBAistration degrees from McGill University and an undergraduate degree from the University of Toronto.
Postes actifs de Giovanni Ferrara
| Sociétés | Poste | Début |
|---|---|---|
Courage Therapeutics, Inc.
 Courage Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops obesity treatment drugs | Directeur Général | 12/06/2025 |
Medeor Therapeutics, Inc.
 Medeor Therapeutics, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for organ transplant recipients | Directeur Général | 01/01/2023 |
Novartis Venture Funds
 Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Private Equity Investor | - |
Anciens postes connus de Giovanni Ferrara
| Sociétés | Poste | Fin |
|---|---|---|
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Private Equity Investor | 15/04/2018 |
Sorbent Therapeutics, Inc.
 Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cardiovascular and renal diseases | Corporate Officer/Principal | 31/12/2011 |
Nucleonics, Inc.
 Nucleonics, Inc. Pharmaceuticals: MajorHealth Technology Develops RNA interference-based therapeutics | Directeur/Membre du Conseil | 04/12/2009 |
Agilix Corp.
 Agilix Corp. Medical SpecialtiesHealth Technology Develops genomics and proteomics platform technologies | Directeur/Membre du Conseil | 05/01/2009 |
Spectral Genomics, Inc.
 Spectral Genomics, Inc. BiotechnologyHealth Technology Develops DNA microarrays and chips used in cloning and genome profiling | Directeur/Membre du Conseil | 31/07/2007 |
Formation de Giovanni Ferrara
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
28
Relations au 1er degré
17
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
Agilix Corp.
Agilix Corp. Medical SpecialtiesHealth Technology Develops genomics and proteomics platform technologies | Health Technology |
Nucleonics, Inc.
Nucleonics, Inc. Pharmaceuticals: MajorHealth Technology Develops RNA interference-based therapeutics | Health Technology |
Sorbent Therapeutics, Inc.
Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cardiovascular and renal diseases | Health Technology |
Thesan Pharmaceuticals, Inc.
 Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces novel therapeutics for skin disorders | Health Technology |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burrill invests in companies located in the United States. The firm focuses on a broad range of sectors. It participates in buyout and early-stage transactions. | Finance |
Letko Brosseau Investment Management, Inc.
 Letko Brosseau Investment Management, Inc. Investment ManagersFinance Provides investment advice | Finance |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Spectral Genomics, Inc.
Spectral Genomics, Inc. BiotechnologyHealth Technology Develops DNA microarrays and chips used in cloning and genome profiling | Health Technology |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Targanta Therapeutics, Inc.
 Targanta Therapeutics, Inc. BiotechnologyHealth Technology Develops antibiotic drugs and other related products | Health Technology |
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Finance |
GeneChem Management, Inc.
 GeneChem Management, Inc. Investment ManagersFinance GeneChem invests in companies located primarily in the US, Canada and Europe. The firm targets companies operating in the fields of biotechnology sectors. It provides financing for seed to later-stage mezzanine rounds and private placements in publicly listed companies. | Finance |
Akebia Therapeutics, Inc.
 Akebia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for kidney diseases | Health Technology |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Finance |
NeuroVia, Inc.
 NeuroVia, Inc. Pharmaceuticals: MajorHealth Technology Provides small molecule therapeutics for the treatment of neurologic disorders | Health Technology |
Medeor Therapeutics, Inc.
Medeor Therapeutics, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for organ transplant recipients | Health Technology |
Courage Therapeutics, Inc.
Courage Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops obesity treatment drugs | Health Technology |
